Currently, no effective treatment exists for this kind of cancer so identifying the gene makes drug development more possible. When the researchers deleted the gene they dubbed POU class 2 homeobox associating factor 2 (POU2AF2), the cancer cells could not survive (Science Advances, October 5, 2022).

The scientists focused on this gene because the POU class 2 homeobox 3 (POU2F3) is a master regulator of tuft cell identity and defines the small cell lung cancer P subtype. A previously uncharacterized protein, C11orf53, is co-expressed with POU2F3 in both SCLC cell lines and patient samples. The protein directly interacts with POU2F3 and is recruited to chromatin by POU2F3.

When C11orf53 is diminished, that also reduces enhancer H3K27ac levels and chromatin accessibility. The result is less POU2F3-dependent gene expression. In other words, no more cancer. Because of the molecular function of C11orf53, the researchers renamed the protein POU2AF2.

Going forward, the scientists want to develop a more personalized approach to SCLC clinical treatment by targeting mechanisms that contribute to tumor growth based on factors that regulate molecular subtypes. They also believe their findings can potentially serve as a biomarker to identify this cancer at earlier stages.

"This type of cancer is resistant to a lot of drugs and not many studies focus on it," lead author Lu Wang, PhD, an assistant professor of biochemistry and molecular genetics at Northwestern University Feinberg School of Medicine, said in a statement. "By identifying this important gene, we now have a very good drug target to work with."

Protein RAF1 structure revealed, opens door to new lung cancer drugs
Using cryo-electron microscopy, researchers at the Spanish National Cancer Research Center (CNIO) and the University of Copenhagen have determined the...

Tuft cell discovery could lead to new way to treat deadly form of small cell lung cancer
Cold Spring Harbor Laboratory researchers have discovered how tuft cells are generated in the body, offering hope that disrupting tuft cell development...

New mutational signatures pinpoint causes of cancer and personalize treatment
New research published on April 11 in Cancer Research has revealed a previously unknown mechanism in a common form of lung cancer that uses epigenetic...

Innovations in synthetic chemistry help identify new cancer therapies
The pathway to discovering and developing cancer therapies is not always linear, but well-designed models incorporating smart chemical innovations can...